RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion" Unlike other approved anti-PD-L1 antibodies, avelumab has a native Fc region that retains FcγR binding capability."
Avelumab is cleared faster and has a shorter half-life than other anti-PD-L1 antibodies, such as atezolizumab and durvalumab, which appears to negatively impact T cell clones expansion. Consequently the addition of the PD-L1 inhibitor avelumab, unlike atezolizumab, eliminated pre-existing TIL expansion in the blood and reduced pelareorep's clinical activity.
https://stockhouse.com/news/press-releases/2024/05/24/oncolytics-biotech-xae-asco-abstracts-highlight-pelareorep-s-potential-in